HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes induce autophagic cell death in estrogen receptor negative breast cancer.

AbstractBACKGROUND:
A novel series of methylene-substituted DIMs (C-DIMs), namely 1,1-bis(3'-indolyl)-1-(p-substituted phenyl)methanes containing t-butyl (DIM-C-pPhtBu) and phenyl (DIM-C-pPhC6H5) groups inhibit proliferation of invasive estrogen receptor-negative MDA-MB-231 and MDA-MB-453 human breast cancer cell lines with IC50 values between 1-5 uM. The main purpose of this study was to investigate the pathways of C-DIM-induced cell death.
METHODS:
The effects of the C-DIMs on apoptotic, necrotic and autophagic cell death were determined using caspase inhibitors, measurement of lactate dehydrogenase release, and several markers of autophagy including Beclin and light chain associated protein 3 expression (LC3).
RESULTS:
The C-DIM compounds did not induce apoptosis and only DIM-C-pPhCF3 exhibited necrotic effects. However, treatment of MDA-MB-231 and MDA-MB-453 cells with C-DIMs resulted in accumulation of LC3-II compared to LC3-I protein, a characteristic marker of autophagy, and transient transfection of green fluorescent protein-LC3 also revealed that treatment with C-DIMs induced a redistribution of LC3 to autophagosomes after C-DIM treatment. In addition, the autofluorescent drug monodansylcadaverine (MDC), a specific autophagolysosome marker, accumulated in vacuoles after C-DIM treatment, and western blot analysis of lysates from cells treated with C-DIMs showed that the Beclin 1/Bcl-2 protein ratio increased.
CONCLUSION:
The results suggest that C-DIM compounds may represent a new mechanism-based agent for treating drug-resistant ER-negative breast tumors through induction of autophagy.
AuthorsKathy Vanderlaag, Yunpeng Su, Arthur E Frankel, Robert C Burghardt, Rola Barhoumi, Gayathri Chadalapaka, Indira Jutooru, Stephen Safe
JournalBMC cancer (BMC Cancer) Vol. 10 Pg. 669 (Dec 03 2010) ISSN: 1471-2407 [Electronic] England
PMID21129193 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • 1,1-bis(3'-indolyl)-1-(4-biphenyl)methane
  • 1,1-bis(3'-indolyl)-1-(4-t-butylphenyl)methane
  • Amino Acid Chloromethyl Ketones
  • Antineoplastic Agents
  • Apoptosis Regulatory Proteins
  • BECN1 protein, human
  • Beclin-1
  • Biomarkers, Tumor
  • Caspase Inhibitors
  • Cysteine Proteinase Inhibitors
  • Indoles
  • Macrolides
  • Membrane Proteins
  • Microtubule-Associated Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Receptors, Estrogen
  • Recombinant Fusion Proteins
  • benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
  • bafilomycin A1
  • L-Lactate Dehydrogenase
  • Caspases
Topics
  • Amino Acid Chloromethyl Ketones (pharmacology)
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Apoptosis (drug effects)
  • Apoptosis Regulatory Proteins (metabolism)
  • Autophagy (drug effects)
  • Beclin-1
  • Biomarkers, Tumor (analysis)
  • Blotting, Western
  • Breast Neoplasms (chemistry, drug therapy, pathology)
  • Caspase Inhibitors
  • Caspases (metabolism)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cysteine Proteinase Inhibitors (pharmacology)
  • Female
  • Humans
  • Immunohistochemistry
  • Indoles (pharmacology)
  • L-Lactate Dehydrogenase (metabolism)
  • Macrolides (pharmacology)
  • Membrane Proteins (metabolism)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Microtubule-Associated Proteins (genetics, metabolism)
  • Necrosis
  • Proto-Oncogene Proteins c-bcl-2 (metabolism)
  • Receptors, Estrogen (analysis)
  • Recombinant Fusion Proteins (metabolism)
  • Time Factors
  • Transfection
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: